Total Funding
44
32
Total FundingPost-IPO Equity raised
Growth Score
-12 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
115701
SAGE Therapeutics develops and delivers novel medicines for most debilitating and disabling central nervous system disorders.
Acquired by 
Supernus Pharmaceuticals
- Eddie Carrillo: Sr. Director, Quality
- Past Role: Lundbeck, Vice President
About the Company
SAGE Therapeutics is dedicated to the health and well being of patients with central nervous system (CNS) disorders. Their mission is to discover, develop and deliver novel medicines for many of today's most debilitating and disabling CNS disorders by leveraging compelling science, a robust clinical foundation, strong partnerships, and a
world-class team of founders, advisors, investors, scientists and managers.
